Truist Financial Increases BeOne Medicines (NASDAQ:ONC) Price Target to $418.00

Key Points

• Truist Financial raised BeOne Medicines’ price target to $418 from $416 and maintained a Buy rating, implying approximately 27.9% upside from the reported $326.90 share price.
• BeOne exceeded quarterly expectations, reporting EPS of $2.05 versus the $1.40 consensus and revenue of $1.71 billion versus $1.66 billion. Analysts’ consensus view remains Moderate Buy, with an average target of $395.92.
• Investor sentiment is broadly positive, but valuation and insider selling remain risks: the stock trades at a P/E ratio of 73, while insiders sold roughly $105.6 million of shares over the past 90 days.

BeOne Medicines (NASDAQ:ONC - Get Free Report) had its price objective hoisted by stock analysts at Truist Financial from $416.00 to $418.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. Truist Financial's price target would indicate a potential upside of 27.87% from the company's current price.

Other equities analysts have also recently issued research reports about the stock. Citigroup reissued an "outperform" rating on shares of BeOne Medicines in a research note on Thursday. Morgan Stanley reissued an "overweight" rating and issued a $395.00 target price on shares of BeOne Medicines in a report on Thursday, May 7th. Weiss Ratings restated a "sell (d-)" rating on shares of BeOne Medicines in a report on Friday, July 17th. Zacks Research downgraded BeOne Medicines from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 3rd. Finally, Royal Bank Of Canada raised their price target on shares of BeOne Medicines from $436.00 to $451.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $395.92.

BeOne Medicines Price Performance

ONC stock traded down $0.63 during mid-day trading on Thursday, hitting $326.90. The stock had a trading volume of 139,726 shares, compared to its average volume of 279,777. The firm has a market capitalization of $35.87 billion, a P/E ratio of 73.00 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a fifty day simple moving average of $294.53 and a 200 day simple moving average of $308.67. BeOne Medicines has a 52 week low of $253.95 and a 52 week high of $385.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. As a group, research analysts forecast that BeOne Medicines will post 5.93 EPS for the current year.

Insider Activity

In related news, COO Xiaobin Wu sold 1,292 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $276.26, for a total transaction of $356,927.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 61,397 shares of BeOne Medicines stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99. Following the completion of the sale, the chief executive officer directly owned 9,180 shares in the company, valued at approximately $2,916,210.60. The trade was a 86.99% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 345,561 shares of company stock worth $105,625,947 in the last ninety days. 6.19% of the stock is owned by insiders.

Institutional Investors Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cetera Investment Advisers acquired a new position in shares of BeOne Medicines during the 2nd quarter worth $455,000. Rhumbline Advisers purchased a new position in BeOne Medicines in the second quarter valued at about $275,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $505,000. Invesco Ltd. purchased a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $422,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter worth approximately $68,000. Institutional investors and hedge funds own 48.55% of the company's stock.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 results exceeded expectations: BeOne reported earnings of $2.05 per share, well above the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. Revenue reportedly surged 30% year over year, signaling strong commercial momentum. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook was raised: Management now expects fiscal-year revenue of $6.6 billion to $6.8 billion, above the $6.5 billion Wall Street forecast. The higher outlook suggests confidence in demand for BeOne’s marketed cancer treatments. BeOne raises 2026 outlook
• Positive Sentiment: Analysts raised targets: Guggenheim lifted its price target from $420 to $430 and assigned a Buy rating, while Citizens JMP raised its target from $396 to $405 and maintained a Market Outperform rating. The revisions reflect stronger earnings and growth expectations. Analyst price-target updates
• Positive Sentiment: Pipeline development advanced: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially supporting faster regulatory engagement and development of the candidate. UK Innovation Passport announcement
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at approximately $362,000 to cover tax withholding associated with vested equity awards. Because the transaction was not described as discretionary, it is a limited bearish signal. SEC insider transaction filing
• Neutral Sentiment: Valuation remains demanding: Despite improving fundamentals and a generally favorable analyst view, ONC trades at a relatively high earnings multiple, leaving the stock sensitive to any slowdown in growth or disappointing pipeline news.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source